What applications does mass spectrometry imaging have in cancer research?
1. Tumor heterogeneity2. Biomarker discovery3. Drug distribution and pharmacology4. Complementarity with in-situ techniques
1. Tumor heterogeneity
The metabolic and lipid distribution within the same tumor is not uniform. High-resolution sources such as LDPI (2–3 μm) can reveal metabolic gradients at the single-cell/subcellular scale, explaining why some regions are drug-resistant or invasive.
Heterogeneity research is a strength of MSI—homogenate sequencing smooths out spatial differences, while imaging preserves them.
2. Biomarker discovery
By comparing molecular maps of cancerous and adjacent tissue, spatially specific lipids/metabolites are screened as potential markers; then imaging is used to verify them back in tissue in situ, forming a 'discovery–verification' closed loop.
Such work is often combined with the cancer vs adjacent-tissue differentiation method to improve marker credibility.
3. Drug distribution and pharmacology
Drug metabolism analysis in cancer manifests as intra-tumor penetration, enrichment and metabolic transformation. MSI directly shows whether a candidate drug reaches the lesion and where it accumulates, supporting optimization of the dosing regimen.
For small-molecule drugs, matrix-free low-background sources (LDPI, DESI) are more suitable than matrix-peak-interfered MALDI.
4. Complementarity with in-situ techniques
MSI provides a molecular spatial map that can be overlaid with H&E/immunohistochemistry to anchor molecular distribution to tissue morphology; it can also connect to spatial omics for systematic analysis.
The value of cancer research lies not in a single pretty image but in a repeatable spatial causal evidence chain.
Frequently Asked Questions (FAQ)
- What is MSI mainly used for in cancer?
- Heterogeneity depiction, biomarker discovery, drug distribution and in-situ verification.
- How to look at tumor heterogeneity?
- Use high-resolution sources to reveal single-cell/subcellular metabolic gradients, explaining drug resistance and invasion.
- Advantages vs homogenate sequencing?
- It preserves spatial differences, is not averaged out, and can show distribution and gradients.
- Notes on small-molecule drug imaging?
- Prioritize matrix-free low-background sources (LDPI/DESI) to avoid matrix interference.
Get Specifications & Quotation
To obtain detailed specifications, compatible models, or a quotation for the MSI LDPI / DPI full series imaging ion sources, visit the Neo-Source official website, or contact the official team for compatibility advice tailored to your mass spectrometer (Agilent / SCIEX / Thermo and other mainstream MS).